Swedbank Ab Bei Gene, Ltd. Transaction History

Swedbank Ab

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 21, 2024	BUY	$141.8 - $181.47 $2.35 Million - $3.01 Million	16,599 New	16,599 $2.6 Billion
Q4 2022 Dec 09, 2024	BUY	$125.51 - $229.3 $482,585 - $881,658	3,845 Added 23.42%	20,264 $4.46 Million
Q4 2021 Dec 09, 2024	BUY	$248.56 - $389.34 $2.74 Million - $4.29 Million	11,021 Added 204.17%	16,419 $4.45 Million
Q2 2021 Dec 09, 2024	BUY	$292.75 - $367.01 $1.58 Million - $1.98 Million	5,398 New	5,398 $1.85 Million

251

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $23.5B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Swedbank Ab, based on Form 13F filings with the SEC.

Stay updated on Swedbank Ab with notifications on news.